<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495181</url>
  </required_header>
  <id_info>
    <org_study_id>ECR-AMD-2015-09</org_study_id>
    <nct_id>NCT02495181</nct_id>
  </id_info>
  <brief_title>Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy</brief_title>
  <acronym>ATLANTIC</acronym>
  <official_title>A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of IV Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With PCV.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association for Innovation and Biomedical Research on Light and Image</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Vision Institute Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Association for Innovation and Biomedical Research on Light and Image</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of intravitreal Aflibercept
      monotherapy with the efficacy and safety of combined treatment with Aflibercept plus standard
      photodynamic therapy (PDT) with Verteporfin in age-related macular degeneration (AMD)
      patients with polypoidal choroidal vasculopathy (PCV).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>from Baseline (Week 0) to Week 52.</time_frame>
    <description>Unit of Measure: [Letters]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polyps regression</measure>
    <time_frame>from Baseline (W0) to Week 52.</time_frame>
    <description>Unit of Measure: [Yes, No]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polyps regression, assessed by Indocyanine Green Angiography (ICGA);</measure>
    <time_frame>from Baseline (W0) to Week 16</time_frame>
    <description>Unit of Measure: [Yes, No]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of active polyps, assessed by Indocyanine Green Angiography (ICGA);</measure>
    <time_frame>from Baseline (W0) to Week 52</time_frame>
    <description>Unit of Measure: [Yes, No]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of leakage based on fluorescein angiography (FA)</measure>
    <time_frame>from Baseline (W0) to Week 52</time_frame>
    <description>Unit of Measure: [Yes, No]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Subfield Central Retinal Thickness (CRT), assessed by Spectral Domain-Optical Coherence Tomography (SD-OCT);</measure>
    <time_frame>from Baseline (W0) to Week 52</time_frame>
    <description>Unit of Measure: [µm]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of fluid assessed on Spectral Domain-Optical Coherence Tomography (SD-OCT) at Week 52;</measure>
    <time_frame>from Baseline (W0) to Week 52</time_frame>
    <description>Unit of Measure: [Yes, No]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of treatments with Aflibercept;</measure>
    <time_frame>from Baseline (W0) to Week 52</time_frame>
    <description>Unit of Measure: [#]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of ocular and non-ocular adverse events over time.</measure>
    <time_frame>from Baseline (W0) to Week 52</time_frame>
    <description>Unit of Measure: [Mild, Moderate, Severe]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Aflibercept + Verteporfin PDT</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>- IVT Aflibercept 2 mg on a Treat &amp; Extend Regimen + Verteporfin PDT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept + Sham PDT</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>IVT Aflibercept 2 mg on a Treat &amp; Extend Regimen + Sham PDT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVT Aflibercept; Verteporfin PDT</intervention_name>
    <arm_group_label>Aflibercept + Verteporfin PDT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVT Aflibercept; Sham PDT</intervention_name>
    <arm_group_label>Aflibercept + Sham PDT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Either gender and Age ≥ 50.

          -  Naïve PCV patients.

          -  Confirmed diagnosis of symptomatic macular PCV in the study eye.

          -  Greatest linear dimension of the lesion of &lt; 5400 mm, assessed by ICG angiography.

          -  BCVA at study entry of 25 to 80 letters (Snellen Equivalent 20/320 to 20/25).

          -  Lesion size in the study eye at study entry:

          -  Presence of PCV assessed by the Central Reading Centre based on ICG with active polyps
             with or without abnormal vascular network.

          -  Women must be using effective contraception, be post-menopausal for at least

          -  months prior to trial entry, or surgically sterile.

          -  Ability to provide written informed consent.

          -  Ability to return for all study visits.

        Exclusion Criteria:

          -  Active inflammation or infection in the study eye.

          -  Uncontrolled intraocular pressure in the study eye.

          -  Ocular condition in the study eye which may impact vision and confound study outcomes
             (e.g. vitreomacular traction, epirretinal membrane with BCVA impact, ocular
             inflammation, retinal vascular diseases like diabetic retinopathy or diabetic macular
             edema).

          -  Presence of centromacular scarring or atrophy indicating irreversible BCVA loss.

          -  Prior treatment of the study eye with anti-VEGF therapy or systemic use of anti-VEGF
             products within 3 months prior to the study entry.

          -  Previous vitrectomy, macular laser treatment, PDT, or intraocular steroids in the
             study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rufino Silva, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association for Innovation and Biomedical Research on Light and Image</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catarina Gomes</last_name>
    <phone>+351 239 480 131</phone>
    <email>cmgomes@aibili.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liliana Carvalho</last_name>
    <phone>+351 239 480 112</phone>
    <email>lcarvalho@aibili.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Braga</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luís Mendonça</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Braga</name>
      <address>
        <city>Braga</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luís Mendonça</last_name>
      <email>luismendonc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AIBILI - Centro de Ensaios Clínicos</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548 Coimbra</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rufino Silva</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Espaço Médico de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3030-163</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>João Figueira</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Leiria</name>
      <address>
        <city>Leiria</city>
        <zip>2400-171</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>João Paulo Castro Sousa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRL - Instituto de Retina e Diabetes de Lisboa</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-085 Lisboa</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulo Rosa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Microcirurgia Ocular</name>
      <address>
        <city>Lisboa</city>
        <zip>1600-209</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Roque</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitgalar de Lisboa Norte, EPE - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Vaz-Pereira</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Vila Franca de Xira - Serviço de Oftalmologia</name>
      <address>
        <city>Lisboa</city>
        <zip>2600-009</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Amaro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Oftalmologia Dr. Gama Pinto</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Ágoas</last_name>
      <email>vagoas@igpinto.min-saude.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto- Hospital de Santo António</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelina Meireles</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de São João, EPE - Serviço de Oftalmologia</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ângela Carneiro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidade Clinica de Retina</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Cava</last_name>
      <email>ccavavalenciano@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bellvitge University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Arias</last_name>
      <email>luisariasbarquet@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Oftalmología Barraquer</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Viver</last_name>
      <email>docsonia@barraquer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Microcirugia Ocular</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anniken Bures</last_name>
      <email>bures@imo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Distefano</last_name>
      <email>laura.distefano@outlook.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Cabrera López</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico Fernandez-Vega</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Fernandez-Vega Sanz Vega Sanz</last_name>
      <email>investigacion@fernandez-vega.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

